An act relating to maintaining patient access to animal-derived thyroid medications
Read first time and referred to the Committee on Health Care
Email me when H 676 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track H 676. By continuing you agree to the Terms and Privacy Policy.
Summary
The measure orders the Office of Professional Regulation, together with the Department of Financial Regulation and relevant stakeholders, to explore ways to maintain access to animal‑derived thyroid medications such as desiccated thyroid extract. It requires the agency to put into place any feasible solutions that do not need new legislation and to submit a report with recommendations to the legislature by January 15, 2027. The goal is to help patients who find these drugs more effective or better tolerated than synthetic alternatives.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about H 676
3 free questions a day, no accountHistory
- Read first time and referred to the Committee on Health Care
Sponsors
- Greg Burtt (R) · sponsor
- David Bosch
- Gregory Burtt
- Robert Hooper
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when H 676 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track H 676 freeOr ask your AI assistant about H 676 directly:
Add to Claude, ChatGPT or Cursor